The U.S. Food and Drug Administration (FDA) approved Pfizer's dualtherapy Caduet [amlodipine besylate (Norvasc)/atorvastatin calcium (Lipitor)] for the simultaneous treatment of hypertension and high cholesterol. According to Pfizer, approximately 30 million people in the United States have both hypertension and elevated levels of low-density lipoprotein (LDL) cholesterol.
Caduet will be available in multiple dosing combinations. In clinical trials, Caduet was well tolerated and has been administered with a variety of antihypertensive medications, including thiazide diuretics, beta-blockers, and angiotensin-converting enzyme inhibitors. The most common side effects reported in clinical trials were mild to moderate, and included fluid retention, headache, dizziness, abdominal pain, and weakness.
Caduet is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases, in women during pregnancy, and in nursing mothers. As with any statin, muscle pain, tenderness, or weakness should be reported.
Copyright Springhouse Corporation Apr 2004
Provided by ProQuest Information and Learning Company. All rights Reserved
Home
A
Cabergoline
